Journal article
Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients
DM Stephens, AS Ruppert, WG Weirda, JA Jones, JA Woyach, K Maddocks, SM Jaglowski, LA Andritsos, JM Flynn, MR Grever, G Lozanski, C Tam, S O'Brien, MJ Keating, N Muthusamy, LV Abruzzo, NA Heerema, JC Byrd
American Journal of Hematology | WILEY | Published : 2015
DOI: 10.1002/ajh.24125
Abstract
Little is known about outcomes of patients with chronic lymphocytic leukemia (CLL) with del(17p13.1) karyotype at diagnosis. We reviewed 114 de novo del(17p13.1) CLL patients seen at our institution. Using proportional hazards models to identify pretreatment clinical variables significantly associated with treatment-free survival (TFS) and overall survival (OS), we developed a simplified risk score for de novo del(17p13.1) CLL patients to predict TFS and OS based on these variables. These scores, particularly the very highest, can be utilized to identify high-risk patients for expedient enrollment on clinical trials. Our data support careful observation for low-risk patients, potentially pre..
View full abstractGrants
Awarded by National Institutes of Health
Funding Acknowledgements
Contract grant sponsors: Four Winds Foundation, D. Warren Brown Foundation; Contract grant sponsor: Mr. and Mrs. Michael Thomas, Harry Mangurian Foundation; Contract grant number: P50 CA140158; Contract grant sponsor: Leukemia and Lymphoma Society.